ClinicalTrials.gg
Sign In
Status unknownNCT02560571Updated Sep 20, 2016

Pre-operative Studies for Prediction of Lymph Nodes Involvement in Endometrial Cancer Patients

A Phase 2 interventional study of ultrasound and blood test in Endometrial Cancer, sponsored by Meir Medical Center. Status unknown at 1 site in Israel. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-20.

Sponsored by Meir Medical Center · Phase 2, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Sep 2016), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The study evaluates pre-operative prediction of the risk for lymph nodes involvement in endometrial cancer patients. Patients will undergo ultrasound exam (bi and three dimensional) and biomarker test - Ca 125, in addition to routine physical and laboratory exams, before surgery.

The sonographic evaluation will include endometrial characteristics and myometrial invasion, pelvic findings and enlarged lymph nodes.

02

Conditions studied

  • Endometrial Cancer
03

In context

Endometrial Neoplasms

1,347 studies on the registry are indexed under Endometrial Neoplasms; 452 are open to participants now.

This study's planned enrollment of 200 is above the median of 70 across 954 interventional studies indexed under Endometrial Neoplasms.

Browse Endometrial Neoplasms studies →

Lead sponsor

Meir Medical Center is the lead sponsor of 400 studies on the registry; 25 are open to participants now.

Browse Meir Medical Center studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Endometrial cancer patients
  • Surgical candidates

Exclusion criteria

Exclusion Criteria:

  • Fertility preservation therapy
  • Contraindication for surgery
  • Stage 2 and higher
05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    all patients

    all study patients will undergo ultrasound and blood test

    Device: ultrasound · Other: blood test

Interventions

  • Deviceultrasound
  • Otherblood test
06

What researchers measure

Primary outcomes

  1. number of participants with positive nodes

    Time frame: 4 weeks after surgery (4-6 weeks from enrollment)

07

Study locations

1 of 1 sites recruiting
  • Meir medical center
    Kfar Saba, Israel
    • Yfat Kadan · Contact
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015 and a primary completion of Oct 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2015
First posted
Sep 25, 2015
Start
Oct 2015
Primary completionEst.
Oct 2020
Last update
Sep 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02560571
Lead sponsor
Meir Medical Center
Responsible party
Yfat kadan (Dr, Meir Medical Center) — Principal investigator
First posted
Sep 25, 2015
Start date
Oct 2015
Primary completion
Oct 2020 (estimated)
Last update
Sep 20, 2016

Study contacts

yfat kadan, md
Contact
yfat_ka@clalit.org.il
972-9-7471575
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Endometrial Neoplasms →

Other studies from this sponsor

Meir Medical Center →

Start the discussion